Warner Pharmaceuticals announced that its subsidiary pharmaceutical ingredient, lanthanum carbonate, has obtained a notice of approval for the listing application. Lanthanum carbonate is used to treat hyperphosphatemia. The activity of lanthanum carbonate as a phosphorus binder depends on the high affinity of lanthanum ions with phosphate. Lanthanum ions are released from carbonate in an acidic environment in the stomach and bind to phosphorus in food to form insoluble lanthanum phosphate, thereby reducing the absorption of phosphorus in the gastrointestinal tract.
华纳药厂：子公司原料药碳酸镧获得上市申请批准通知书
Warner Pharmaceuticals: The subsidiary pharmaceutical ingredient lanthanum carbonate received a notice of approval for the listing application
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.